Logo

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

Share this

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

Shots:

  • The new analysis from the clinical trial data evaluates Livmarli (IBAT inhibitor) vs natural history cohort in patients with alagille syndrome. The extensive real-world analysis conducted by GALA & results was presented at AASLD 2021
  • The results showed a high improvement in 6yrs. event-free survival, 70% overall reduction for clinical outcomes with Livmarli, improvements in transplant-free survival & helps to support the impact of LIVMARLI in the patient population
  • Livmarli has received the BTD for ALGS & PFIC type 2 and ODD for ALGS, PFIC & biliary atresia while MAA is currently under review. The company plans to launch the therapy in the EU in H2’22, if approved by EMA

  Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions